Lucentis Injection, Solution
Product Images NDC 50242-080

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Lucentis (NDC 50242-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Lucentis 01)

An illustration of a medication box with a label indicating a dosage of 0.5 mg. The image shows the box partially open, but specific product branding or details are not visible.*

FDA Label Image

Figure (Lucentis 02)

LUCENTIS (ranibizumab) injection solution, showing a clear syringe. The image depicts a pre-filled syringe intended for intravitreal administration, associated with Genentech, Inc. No concentration or volume labeling is visible on the syringe itself.*

FDA Label Image

Figure (Lucentis 03)

Packaging label of LUCENTIS injection solution showing a partial view of a white box with an orange label text indicating 0.3 mg. The product is an intravitreal injection containing ranibizumab and is labeled by Genentech, Inc.*

FDA Label Image

Figure (Lucentis 04)

Illustration of an ophthalmic injection syringe with an orange safety cap, used for administering intravitreal injection solutions such as ranibizumab. The syringe features a clear barrel, measurement markings, and an orange plunger designed for precise dosing.*

FDA Label Image

Figure 1 (Lucentis 05)

An instructional diagram of a syringe used for injection, showing labeled parts including Syringe Cap, Rubber Stopper, Finger Grip, Plunger Rod, Luer Lock, and a 0.05 mL Dose Mark on the barrel.*

FDA Label Image

Figure 2 (Lucentis 06)

An instructional black-and-white line drawing showing a hand holding an intravitreal injection syringe. The drawing illustrates snapping off the syringe cap just before injection, labeled as Figure 2, related to LUCENTIS (ranibizumab) administration.*

FDA Label Image

Figure 3 (Lucentis 07)

An instructional diagram showing a step-by-step procedure involving a syringe or injection device. The images depict removal and attachment steps, including pulling, twisting, and securing components of the device, relevant for preparation of an intravitreal injection.*

FDA Label Image

Figure 4 (Lucentis 08)

An instructional illustration showing a hand holding a syringe with an intravitreal injection solution. The inset highlights an air bubble inside the syringe barrel. The image is labeled as Figure 4 and appears to demonstrate proper syringe handling or air bubble identification before injection.*

FDA Label Image

Figure 5 (Lucentis 09)

An instructional diagram showing the plunger of a syringe for LUCENTIS (ranibizumab) injection, solution. The image highlights the 0.05 mL measurement mark on the syringe barrel, indicating the precise volume to be administered intravitreally.*

FDA Label Image

Figure (Lucentis 10)

An instructional illustration showing two steps for using the LUCENTIS injection vial. The first step depicts inserting a syringe needle vertically down into the vial. The second step shows the vial tilted at an angle with the syringe needle inside, indicating preparation for withdrawal of the solution. This guides proper handling of the intravitreal injection solution.*

FDA Label Image

Figure (Lucentis 11)

An instructional illustration showing a syringe being inserted into a vial. An arrow indicates the direction, likely demonstrating withdrawal of medication from the vial into the syringe. No text or branding is visible in the image.*

FDA Label Image

Figure (Lucentis 12)

An instructional diagram illustrating the preparation of an intravitreal injection syringe for LUCENTIS (ranibizumab). The sequence shows removing the cap from the syringe, twisting a component to unlock, and removing the needle cap to expose the needle for injection.*

FDA Label Image

Figure (Lucentis 13)

An instructional illustration showing a hand holding a syringe with the other hand flicking the top of the syringe plunger. The image appears to demonstrate a technique for preparing an injection, likely for intravitreal administration. No text or specific drug details are shown.*

FDA Label Image

Figure (Lucentis 14)

A black and white line drawing of a syringe with a needle attached, showing a measurement mark at 0.05 mL on the barrel, indicated by an arrow pointing to the mark. The image highlights the precise volume of 0.05 mL for injection use.*

FDA Label Image

Figure 1 (Lucentis 15)

Two line graphs labeled AMD-1 and AMD-2 display mean change in visual acuity over 24 months. The x-axes represent months, and the y-axes show mean change in letters. Data compare LUCENTIS 0.5 mg treatment (black squares/triangles) with sham control (open circles/dots). LUCENTIS shows positive change while sham shows decline in visual acuity.*

FDA Label Image

Figure 2 (Lucentis 16)

A line graph showing mean change in visual acuity (letters) over 12 months for LUCENTIS 0.5 mg compared to sham treatment in an AMD-3 study. Data points for LUCENTIS show improvement, while sham data shows decline in visual acuity over time.*

FDA Label Image

Figure 3 (Lucentis 17)

A line graph titled 'AMD-4' comparing mean change in visual acuity (letters) over 24 months between two dosing regimens of LUCENTIS 0.5 mg: monthly dosing and less frequent than monthly, each with 275 patients.*

FDA Label Image

Figure 4 (Lucentis 18)

A bar chart depicting the percentage of patients versus the number of injections received. The x-axis represents the number of injections from 0 to 22, and the y-axis shows the percentage of patients, peaking around 6-7%. A vertical dashed line indicates the mean number of injections at 10.3.*

FDA Label Image

Figure 5 (Lucentis 19)

Two line graphs titled RVO-1 and RVO-2 showing mean change in visual acuity (letters) over 6 months. Both graphs compare LUCENTIS 0.5 mg treatment groups with sham groups, with LUCENTIS groups showing greater improvement. Numeric values at 6 months indicate approx +18.3 and +14.9 letter improvements for LUCENTIS in RVO-1 and RVO-2 respectively, compared to sham groups with smaller gains.*

FDA Label Image

Figure 6 (Lucentis 20)

Two line charts labeled D-1 and D-2 showing mean change in visual acuity (letters) over 36 months. Both charts compare LUCENTIS 0.3 mg injection (solid squares) versus sham control (open circles). The x-axis represents months and the y-axis represents mean change in visual acuity letters. The charts highlight a treatment crossover from sham to LUCENTIS after about month 24.*

FDA Label Image

Figure 7 (Lucentis 21)

Two sets of bar charts labeled D-1 and D-2, showing percentage data for patient groups over times from Month 3 to Month 36. The charts compare treatment groups including Sham, Sham 0.5 mg, and 0.3 mg Ranibizumab, with statistical significance values (p-values) noted above bars. The x-axes represent time in months, and the y-axes show percentage of patients or patient counts.*

FDA Label Image

Figure 8 (Lucentis 22)

A bar graph comparing the percentage of eyes showing ≥3-step and ≥2-step improvement over Years 1 and 2 for two groups: eyes with baseline DME (n=41) and eyes without baseline DME (n=148). Percentages and upper 95% confidence intervals are displayed for each group and time point.*

FDA Label Image

Figure 9 (Lucentis 23)

A line graph depicting the mean change in best-corrected visual acuity (BCVA) from baseline in letters on the ETDRS scale over a 3-month period. The graph compares three groups: Ranibizumab Group 1 and Group 2, both showing increasing improvement, and a Control (vPDT) group, showing minimal change. The x-axis represents time in months, and the y-axis represents letters ETDRS gained.*

FDA Label Image

Principal Display Panel (0.5 mg Syringe Label)

LUCENTIS Ranibizumab Injection 0.5 mg dose prefilled syringe label. The sterile, single-use intravitreal injection is indicated for neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). Labeler is Genentech, Inc. The label includes storage instructions to keep refrigerated, not freeze, and protect from light.*

FDA Label Image

Principal Display Panel (0.3 mg Syringe Packet)

LUCENTIS ranibizumab injection prefilled syringe label showing a 0.3 mg dose strength. The label highlights use for diabetic macular edema (DME) and diabetic retinopathy (DR), specifies intravitreal injection route, and includes storage instructions to keep refrigerated, avoid freezing, and protect from light. The product is labeled by Genentech, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.